Literature DB >> 33825929

Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer.

Yuki Himoto1, Yulia Lakhman2, Shinya Fujii3, Satoshi Morita4, Jennifer J Mueller5, Mario M Leitao5, Aki Kido6.   

Abstract

PURPOSE: To compare the diagnostic performance of biparametric magnetic resonance imaging (bpMRI) versus multiparametric MRI (mpMRI) for the staging of well-differentiated endometrioid endometrial cancer (EC) in potential candidates for fertility-sparing management.
METHODS: This multi-center retrospective study included 48 potential candidates for fertility-sparing management (age <46 years, grade 1 endometroid EC) who did not wish to undergo fertility-sparing management and thus underwent definitive surgery. Two readers (R1, R2) independently reviewed bpMRI (T1, T2, and diffusion-weighted imaging) and mpMRI (bpMRI and dynamic contrast-enhanced imaging, DCE) during two separate sessions spaced one month apart for the presence of myometrial invasion (MI), cervical stromal involvement (CSI), malignant adnexal disease (mAD), and pelvic lymphadenopathy (pLNM). Each reader also recorded maximum tumor diameter, tumor volume, and tumor-to-uterine volume ratio (TVR) on T2-weighted imaging. The diagnostic performance of bpMRI and mpMRI was determined for each reader with surgical pathology serving as a gold standard.
RESULTS: The area under the receiver operating curve (AUC) for bpMRI versus mpMRI was 0.76/0.78 (R1/R2) versus 0.84/0.83 for MI, 0.79/0.76 versus 0.99/0.80 for CSI, 0.84/0.84 versus 0.84/0.80 for mAD, and 0.82/0.82 for pLMN. The sensitivity and specificity of MRI for detecting tumor spread beyond the endometrium were 71%/77% and 71%/65% for bpMRI (R1/R2) vs. 84%/90% and 71%/65% for mpMRI (R1/R2), respectively. The AUC of maximum tumor diameter, tumor volume, and TVR for MI was 0.71/0.61, 0.73/0.75, and 0.75/0.77 for R1/R2, respectively.
CONCLUSION: MRI had moderate diagnostic performance across potential candidates for fertility-sparing treatment of EC. mpMRI outperformed bpMRI for detecting EC spreading beyond the endometrium.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Endometrial cancer; Fertility preservation; Magnetic resonance imaging; Patient selection

Mesh:

Year:  2021        PMID: 33825929     DOI: 10.1007/s00261-021-03050-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  19 in total

Review 1.  MRI characteristics of the uterine junctional zone: from normal to the diagnosis of adenomyosis.

Authors:  Sébastien Novellas; Madleen Chassang; Jerome Delotte; Olivier Toullalan; Anne Chevallier; Jerome Bouaziz; Patrick Chevallier
Journal:  AJR Am J Roentgenol       Date:  2011-05       Impact factor: 3.959

2.  Influence of menopausal status on diagnostic accuracy of myometrial invasion in endometrial cancer: diffusion-weighted and dynamic contrast-enhanced MRI at 3 T.

Authors:  G Lin; Y-T Huang; A Chao; K-K Ng; L-Y Yang; S-H Ng; C-H Lai
Journal:  Clin Radiol       Date:  2015-07-29       Impact factor: 2.350

3.  Assessment of Myometrial Invasion in Premenopausal Grade 1 Endometrial Carcinoma: Is Magnetic Resonance Imaging a Reliable Tool in Selecting Patients for Fertility-Preserving Therapy?

Authors:  Makoto Sakane; Masatoshi Hori; Hiromitsu Onishi; Takahiro Tsuboyama; Takashi Ota; Mitsuaki Tatsumi; Yutaka Ueda; Toshihiro Kimura; Tadashi Kimura; Noriyuki Tomiyama
Journal:  J Comput Assist Tomogr       Date:  2018 May/Jun       Impact factor: 1.826

4.  Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment?

Authors:  Isabelle Navarria; Massimo Usel; Elisabetta Rapiti; Isabelle Neyroud-Caspar; Marie-Françoise Pelte; Christine Bouchardy; Patrick Petignat
Journal:  Gynecol Oncol       Date:  2009-06-27       Impact factor: 5.482

5.  Coexisting ovarian malignancy in young women with endometrial cancer.

Authors:  Christine Walsh; Christine Holschneider; Yen Hoang; Khai Tieu; Beth Karlan; Ilana Cass
Journal:  Obstet Gynecol       Date:  2005-10       Impact factor: 7.661

6.  Prognostic factors for uterine cancer in reproductive-aged women.

Authors:  Nita Karnik Lee; Michael K Cheung; Jacob Y Shin; Amreen Husain; Nelson N Teng; Jonathan S Berek; Daniel S Kapp; Kathryn Osann; John K Chan
Journal:  Obstet Gynecol       Date:  2007-03       Impact factor: 7.661

7.  Endometrial cancer in women 40 years old or younger.

Authors:  L R Duska; A Garrett; B R Rueda; J Haas; Y Chang; A F Fuller
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

8.  Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms.

Authors:  Yasuhiko Ebina; Hidetaka Katabuchi; Mikio Mikami; Satoru Nagase; Nobuo Yaegashi; Yasuhiro Udagawa; Hidenori Kato; Kaneyuki Kubushiro; Kiyoshi Takamatsu; Kazuhiko Ino; Hiroyuki Yoshikawa
Journal:  Int J Clin Oncol       Date:  2016-04-26       Impact factor: 3.402

Review 9.  Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology.

Authors:  Stephanie Nougaret; Mariana Horta; Evis Sala; Yulia Lakhman; Isabelle Thomassin-Naggara; Aki Kido; Gabriele Masselli; Nishat Bharwani; Elizabeth Sadowski; Andrea Ertmer; Milagros Otero-Garcia; Rahel A Kubik-Huch; Teresa M Cunha; Andrea Rockall; Rosemarie Forstner
Journal:  Eur Radiol       Date:  2018-07-11       Impact factor: 5.315

Review 10.  Fertility-preservation in endometrial cancer: is it safe? Review of the literature.

Authors:  Márcia Mendonça Carneiro; Rívia Mara Lamaita; Márcia Cristina França Ferreira; Agnaldo Lopes Silva-Filho
Journal:  JBRA Assist Reprod       Date:  2016-12-01
View more
  1 in total

1.  Peritumoral Enhancement for the Evaluation of Myometrial Invasion in Low-Risk Endometrial Carcinoma on Dynamic Contrast-Enhanced MRI.

Authors:  Tingting Cui; Feng Shi; Bei Gu; Yanfang Jin; Jinsong Guo; Chao Zhang; Jie Ren; Yunlong Yue
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.